Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR-Based β-Cell Replacement and Treg Immune Modulation Approaches.
Lin TM, Chang HF, Lin TC, Lin CH, Sun YL
Crispr
The same CRISPR scissors being refined in these diabetes trials are the exact tools crop scientists use to engineer blight-resistant tomatoes, drought-tolerant wheat, and allergen-free peanuts — every safety lesson learned in the clinic accelerates what reaches your vegetable garden.
Type 1 Diabetes destroys the cells in the pancreas that make insulin, forcing people to inject it for life. Scientists are now testing whether CRISPR gene editing can rebuild those cells and simultaneously teach the immune system to leave them alone. Early human trials show the approach is safe so far, but researchers still need to prove it works long-term and can be made available at scale.
Key Findings
Five active clinical trials (including NCT03162237 and NCT06938334) are testing CRISPR-edited cell replacement and immune-modulation strategies, with early-phase data confirming feasibility and acceptable safety profiles.
Two main genetic targets — PD-L1 (immune checkpoint) and FOXP3 (regulatory T-cell master gene) — are being used to suppress the autoimmune attack without broadly disabling the immune system.
Critical unresolved risks include CRISPR off-target edits, insertional mutagenesis from viral gene delivery, and infection/rejection concerns tied to pig-to-human (xenotransplantation) cell sources.
chevron_right Technical Summary
Researchers review how CRISPR gene editing and gene therapy could cure Type 1 Diabetes by regrowing insulin-producing cells and retraining the immune system to stop attacking them, summarizing five ongoing clinical trials and the key hurdles still to overcome.
Abstract Preview
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease marked by the destruction of pancreatic β-cells, resulting in lifelong dependence on exogenous insulin. Despite advances in insulin d...
open_in_new Read full abstractAbstract copyright held by the original publisher.
Was this useful?
Chloroplast Genome Editing Eliminates Gluten Immunogenicity in Triticum aestivum
It could mean that people with celiac disease — roughly 1 in 100 worldwide — may one day safely eat bread made from real wheat, without sacrificing the taste...